Importantly, these clinical reports indicate that therapeutic targets and strategies additional to TRPM3 and LDN are required for ME/CFS, as 13.8% of patients in Polo et al.’s study were unresponsive to LDN, and a further 4.6% discontinued treatment because of adverse symptoms during the introductory phase [132]. The gene discussed is TRPM3; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.